Cited by 203Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingUbiquitin and proteasome pathways

The DOI matches its Crossref record; 94 of the 96 references it cites were found in a registry or an index.

Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson’s disease

McNaught, Kevin St. P., Olanow, C. Warren·2003·Annals of Neurology

DOI 10.1002/ana.10512

Open this paper in CoChat — free account

Abstract

The etiopathogenesis of Parkinson's disease (PD) has been elusive. Recently, several lines of evidence have converged to suggest that defects in the ubiquitin-proteasome system and proteolytic stress underlie nigral pathology in both familial and sporadic forms of the illness. In support of this concept, mutations in alpha-synuclein that cause the protein to misfold and resist proteasomal degradation cause familial PD. Similarly, mutations in two enzymes involved in the normal function of the ubiquitin-proteasome system, parkin and ubiquitin C-terminal hydrolase L1, are also associated with hereditary PD. Furthermore, structural and function defects in 26/20S proteasomes with accumulation and aggregation of potentially cytotoxic abnormal proteins have been identified in the substantia nigra pars compacta of patients with sporadic PD. Thus, a defect in protein handling appears to be a common factor in sporadic and the various familial forms of PD. This hypothesis may also account for the vulnerability of the substantia nigra pars compacta in PD, why the disorder is age related, and the nature of the Lewy body. It has also facilitated the development of experimental models that recapitulate the behavioral and pathological features of PD, and hopefully will lead to the development of novel neuroprotective therapies for the disorder.

Integrity signals

Registry

Crossref · 10.1002/ana.10512

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R. S., Sherer, T., MacKenzie, G. M., Garcia‐Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,770
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Mechanisms Underlying Ubiquitination
Pickart, C. M. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.503 · Cited by 3,184
α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 2,868
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,209
A Drosophila model of Parkinson's disease
Feany, M. Β., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,156
Aggresomes: A Cellular Response to Misfolded Proteins
Johnston, J. A., Ward, C. L., & Kopito, R. R. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.7.1883 · Cited by 2,148
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024

Show all 96 references

Research works printed but not linked: 1

Lee, 2001, J Biol Chem, 27, 27

Sorted by citations

Items 101–200 of 203

The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease
McNaught, K. S. P., JnoBaptiste, R., Jackson, T., & Jengelley, T. (2009) · Synapse · doi:10.1002/syn.20719 · Cited by 37
Self-citation
Akt/Nrf2 Activated Upregulation of Heme Oxygenase-1 Involves in the Role of Rg1 Against Ferrous Iron-Induced Neurotoxicity in SK-N-SH Cells
Du, X., Xu, H., Jiang, H. F., & Xie, J. (2012) · Neurotoxicity Research · doi:10.1007/s12640-012-9362-3 · Cited by 35
Dyrk1A phosphorylates parkin at Ser‐131 and negatively regulates its ubiquitin E3 ligase activity
Im, E., & Chung, K. C. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13164 · Cited by 34
Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole
Albrecht, S., & Buerger, E. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903364954 · Cited by 34
Review: The ubiquitin-proteasome system: contributions to cell death or survival in neurodegeneration
Rogers, N. K., Paine, S., Bedford, L. E., & Layfield, R. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01063.x · Cited by 33
Neuroprotection in parkinson’s disease: An elusive goal
Koller, W. C., & Cersosimo, M. G. (2004) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-004-0052-2 · Cited by 33
Accumulation of phosphorylated tyrosine hydroxylase into insoluble protein aggregates by inhibition of an ubiquitin-proteasome system in PC12D cells
Kawahata, I., Tokuoka, H., Parvez, H., & Ichinose, H. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0304-z · Cited by 31
Redox Modulations, Antioxidants, and Neuropsychiatric Disorders
Fraunberger, E. A., Scola, G., Laliberte, V. L. M., Duong, A., & Andreazza, A. C. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/4729192 · Cited by 36
Downregulation of Parkin Damages Antioxidant Defenses and Enhances Proteasome Inhibition-Induced Toxicity in PC12 Cells
Yang, H., Zhou, H., Li, B., Niu, G., & Chen, S. (2007) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-007-9082-2 · Cited by 32
Lymphocyte Proteomics of Parkinson‘s Disease Patients Reveals Cytoskeletal Protein Dysregulation and Oxidative Stress
Mila, S., Albo, A. G., Corpillo, D., Giraudo, S., Zibetti, M., Bucci, E. M., Lopiano, L., & Fasano, M. (2009) · Biomarkers in Medicine · doi:10.2217/bmm.09.4 · Cited by 32
Inhibition of monoamine oxidase by 8-[(phenylethyl)sulfanyl]caffeine analogues
Mostert, S., Mentz, W., Petzer, A., Bergh, J. J., & Petzer, J. P. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.10.005 · Cited by 31
Mutant genes responsible for Parkinson's disease
Le, W. (2003) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.09.005 · Cited by 31
α-synuclein and Parkinson’s disease: a proteomic view
Fasano, M., & Lopiano, L. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.239 · Cited by 31
Future directions in the treatment of Parkinson's disease
Schapira, A. H. V. (2007) · Movement Disorders · doi:10.1002/mds.21679 · Cited by 30
Intragastric proteasome inhibition induces alpha-synuclein-immunopositive aggregations in neurons in the dorsal motor nucleus of the vagus in rats
Miwa, H., Kubo, T., Suzuki, A., & Kondo, T. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.03.003 · Cited by 30
Redox proteomics and drug development
D’Alessandro, A., Rinalducci, S., & Zolla, L. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.01.001 · Cited by 27
Coenzyme Q10 and its effects in the treatment of neurodegenerative diseases
dos Santos, G. C., Antunes, L. M. G., dos Santos, A. C., & Bianchi, M. D. L. P. (2009) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502009000400002 · Cited by 28
The activation sequence of cellular protein handling systems after proteasomal inhibition in dopaminergic cells
Xiong, R., Siegel, D. M., & Ross, D. (2013) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2013.04.016 · Cited by 24
Compensatory role of the Nrf2–ARE pathway against paraquat toxicity: Relevance of 26S proteasome activity
Izumi, Y., Yamamoto, N., Matsushima, S., Yamamoto, T., Takada‐Takatori, Y., Akaike, A., & Kume, T. (2015) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2015.09.003 · Cited by 24
Environmental Toxins and α-Synuclein in Parkinson's Disease
Liu, Y., & Yang, H. (2005) · Molecular Neurobiology · doi:10.1385/mn:31:1-3:273 · Cited by 23
Proteolytic Dysfunction in Neurodegenerative Disorders
McNaught, K. S. P. (2004) · International review of neurobiology · doi:10.1016/s0074-7742(04)62003-4 · Cited by 24
Self-citation
Neuronal inclusions in degenerative disorders
Fornai, F., Soldani, P., Lazzeri, G., di Poggio, A. B., Biagioni, F., Fulceri, F., Batini, S., Ruggieri, S. A., & Paparelli, A. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2004.12.009 · Cited by 22
Connecting the dots between mitochondrial dysfunction and Parkinson’s disorder: focus mitochondria-targeting therapeutic paradigm in mitigating the disease severity
Kaur, I., Behl, T., Sehgal, A., Singh, S., Sharma, N., Aleya, L., & BUNGAU, S. G. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-14619-6 · Cited by 20
Neuroprotective effect of modified Chungsimyeolda-tang, a traditional Korean herbal formula, via autophagy induction in models of Parkinson׳s disease
Bae, N.-Y., Chung, S., Kim, H., Cha, J. W., Oh, H., Gu, M., Oh, M. S., & Yang, H. O. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.11.007 · Cited by 21
History of Parkinson's disease
Goldman, J. G., & Goetz, C. G. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83005-3 · Cited by 21
Lewy Body Disorders
Jellinger, K. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-30377-2_15 · Cited by 22
An analysis of genetic studies of Parkinson's disease in Africa
Okubadejo, N. U. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.08.006 · Cited by 21
Adhesion Molecule L1 Agonist Mimetics Protect Against the Pesticide Paraquat-Induced Locomotor Deficits and Biochemical Alterations in Zebrafish
Joseph, T. P., Jagadeesan, N., Sai, L., Lin, S. L., Sahu, S. S., & Schachner, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00458 · Cited by 20
Proteomic insights into the protective mechanisms of an in vitro oxidative stress model of early stage Parkinson's disease
Bauereis, B., Haskins, W. E., LeBaron, R. G., & Renthal, R. D. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.10.071 · Cited by 20
Disease-Toxicant Interactions in Parkinson’s Disease Neuropathology
Kwakye, G. F., McMinimy, R. A., & Aschner, M. (2016) · Neurochemical Research · doi:10.1007/s11064-016-2052-4 · Cited by 21
Parkinson's disease: A broken nosology
Hardy, J., & Lees, A. J. (2005) · Movement Disorders · doi:10.1002/mds.20532 · Cited by 19
Adverse Outcome Pathway on Inhibition of the mitochondrial complex I of nigro-striatal neurons leading to parkinsonian motor deficits
Bal‐Price, A., Leist, M., Schildknecht, S., Monnet‐Tschudi, F., Paini, A., & Terron, A. (2018) · OECD series on adverse outcome pathways · doi:10.1787/b46c3c00-en · Cited by 22
The molecular mechanism of three novel peptides from C-phycocyanin alleviates MPTP-induced Parkinson's disease-like pathology in zebrafish
Xu, F., Qiu, Y., Zhang, Y., Yang, F., Ji, M.-M., Liu, K., Jin, M., Zhang, S., & Li, B. (2023) · Food & Function · doi:10.1039/d3fo01098h · Cited by 18
Molecular Mechanisms of Neurodegeneration in Parkinson's Disease: Clues from Mendelian Syndromes
Lim, K. L., & Lim, T. M. (2003) · IUBMB Life · doi:10.1080/1521654031000153030 · Cited by 18
Clinical and molecular neuroimaging characteristics of Brazilian patients with Parkinson's disease and mutations in PARK2 or PARK8 genes
Barsottini, O. G. P., Felicio, A. C., Aguiar, P. D. C., Godeiro-Junior, C. D. O., Shih, M. C., Hoexter, M. Q., Bressan, R. A., Ferraz, H. B., & Andrade, L. E. C. (2009) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2009000100003 · Cited by 18
Recent advances in our understanding of Parkinson's disease
Kim, S. W., Ko, H. S., Dawson, V. L., & Dawson, T. M. (2005) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2005.11.015 · Cited by 17
Excess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1
Shimshek, D. R., Schweizer, T., Schmid, P., & van der Putten, P. H. (2012) · Scientific Reports · doi:10.1038/srep00262 · Cited by 16
Striatal 19S Rpt6 deficit is related to α-synuclein accumulation in MPTP-treated mice
Liu, B., Shi, Q., Ma, S., Feng, N., Li, J., Wang, L., & Wang, X. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.142 · Cited by 16
Role of the p62 Protein in the Formation of Neuropathological Cytoplasmic Inclusions
Kuusisto, E. (2004) · Cited by 16
Enzymatic synthesis of l-DOPA α-glycosides by reaction with sucrose catalyzed by four different glucansucrases from four strains of Leuconostoc mesenteroides
Yoon, S., Fulton, D. B., & Robyt, J. F. (2010) · Carbohydrate Research · doi:10.1016/j.carres.2010.05.001 · Cited by 15
Etiopatogenia da Doença de Parkinson
Teive, H. A. (2019) · Revista Neurociências · doi:10.34024/rnc.2005.v13.8794 · Cited by 15
Integrative genomics analysis identifies five promising genes implicated in insomnia risk based on multiple omics datasets
Sun, H., Zhang, J., Ma, Y., & Liu, J. (2020) · Bioscience Reports · doi:10.1042/bsr20201084 · Cited by 14
Failure of acute administration with proteasome inhibitor to provide a model of Parkinson’s disease in mice
Kadoguchi, N., Kimoto, H., Yano, R., Kato, H., & Araki, T. (2008) · Metabolic Brain Disease · doi:10.1007/s11011-008-9082-9 · Cited by 14
1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure fails to produce delayed degeneration of substantia nigra neurons in monkeys
Garrido‐Gil, P., Belzunegui, S., Sebastián, W. S., Izal‐Azcárate, A., López, B., Marcilla, I., & Luquín, M. R. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21845 · Cited by 14
UCH-L1 in Alzheimer’s Disease: A Crucial Player in Dementia-Associated Mechanisms
Porchietto, E., Morello, G., Cicilese, G., Rainero, I., Rubino, E., Tamagno, E., Boschi, S., & Guglielmotto, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189012 · Cited by 13
Diseases of movement and system degenerations
Ince, P. G., Clark, B., Holton, J. L., Révész, T., & Wharton, S. B. (2008) · CRC Press eBooks · doi:10.1201/b13319-14 · Cited by 13
Dynamic Metabolic and Transcriptional Responses of Proteasome-Inhibited Neurons
Suciu, I., Delp, J., Gutbier, S., Ückert, A.-K., Spreng, A.-S., Eberhard, P., Karreman, C., Schreiber, F., Madjar, K., Rahnenführer, J., et al. (2023) · Antioxidants · doi:10.3390/antiox12010164 · Cited by 11
Neuroprotection of Parkin against apoptosis is independent of inclusion body formation
Yang, H., Zhou, H., Li, B., & Chen, S. (2005) · Neuroreport · doi:10.1097/00001756-200507130-00017 · Cited by 11
The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells
Maruyama, W., Shamoto‐Nagai, M., Akao, Y., Riederer, P. F., & Naoi, M. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_20 · Cited by 11
Impact of α-Synuclein Pathology on Aging
Parkkinen, L. (2005) · Cited by 11
Accurate identification of genes associated with brain disorders by integrating heterogeneous genomic data into a Bayesian framework
He, D., Li, L., Zhang, H., Liu, F., Li, S., Xiu, X., Fan, C., Qi, M., Meng, M., Ye, J., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105286 · Cited by 12
NAC1, A POZ/BTB protein interacts with Parkin and may contribute to Parkinson’s disease
Korutla, L., Furlong, H. A., & Mackler, S. A. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.11.001 · Cited by 10
PINK1 mutations in a Brazilian cohort of early‐onset Parkinson's disease patients
Godeiro-Junior, C. D. O., Aguiar, P. D. C., Felicio, A. C., Barsottini, O. G. P., Silva, S. M. A., Borges, V., de Andrade, L. A. F., & Ferraz, H. B. (2009) · Movement Disorders · doi:10.1002/mds.22685 · Cited by 10
Synthesis of dopamine and l-DOPA-α-glycosides by reaction with cyclomaltohexaose catalyzed by cyclomaltodextrin glucanyltransferase
Yoon, S., Fulton, D. B., & Robyt, J. F. (2009) · Carbohydrate Research · doi:10.1016/j.carres.2009.06.041 · Cited by 8
Systemic proteasomal inhibitor exposure enhances dopamine turnover and decreases dopamine levels but does not affect MPTP‐induced striatal dopamine depletion in mice
Hirst, S. J., & Ferger, B. (2007) · Synapse · doi:10.1002/syn.20457 · Cited by 8
Autonomic dysfunction in early and advanced Parkinson's disease
Pursiainen, V. (2007) · Cited by 8
The Role of the Ubiquitination Machinery in Dislocation and Degradation of Endoplasmic Reticulum Proteins
Kikkert, M., Hassink, G. C., & Wiertz, E. J. H. J. (2006) · Springer eBooks · doi:10.1007/3-540-28007-3_4 · Cited by 7
Mitochondria in the etiology of Parkinson's disease
Schapira, A. H. V. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83022-3 · Cited by 7
Music and Dopamine – Potential in Movement Disorders
Kawahata, K., Kawahata, K., Hasegawa, K., & Kase, R. (2020) · Journal of Brain and Nerves · doi:10.31487/j.jbn.2020.01.02 · Cited by 5
Current concepts on the etiology and pathogenesis of Parkinson disease
Fahn, S., Jankovic, J. J., & Hallett, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-2369-4.00005-6 · Cited by 5
Proteasome Inhibitor Lactacystin Induces Cholinergic Degeneration
Zhou, H.-Y., Tan, Y.-Y., Wang, Z., Wang, G., Lu, G.-Q., & Chen, S.-D. (2010) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100009975 · Cited by 4
Proteasomal inhibition and apoptosis regulatory changes in human isolated lymphocytes: The synergistic role of dopamine
Bazzini, E., Samuele, A., Granelli, M., Levandis, G., Armentero, M., Nappi, G., & Blandini, F. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21457 · Cited by 4
The Ubiquitin–Proteasome System in Parkinson's Disease
McNaught, K. S. P. (2007) · Wiley eBooks · doi:10.1002/9783527620234.ch8 · Cited by 4
Self-citation
Alteration of Striatal Tetrahydrobiopterin in Iron-Induced Unilateral Model of Parkinson's Disease
Aryal, B., Lee, J.-K., Kim, H. R., & Kim, H. (2014) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2014.18.2.129 · Cited by 3
Modèles animaux des syndromes parkinsoniens
Ghorayeb, I., Bézard, E., Fernagut, P., Bioulac, B. H., & Tison, F. (2005) · Revue Neurologique · doi:10.1016/s0035-3787(05)85154-9 · Cited by 2
Spheramine®: A Cell Therapeutic Approach to Parkinson's Disease
Reissig, E., Hermann, G. R. A. F., & Kapp, F. (2005) · doi:10.1002/9783527620982.ch14 · Cited by 2
Immunoproteasome Activity in the Nervous System
RINAUDO, M. T., & Piccinini, M. (2007) · Springer eBooks · doi:10.1007/978-0-387-30398-7_9 · Cited by 1
Quinone Reductases
Ross, D., & Siegel, D. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00411-5 · Cited by 1
Protein‐handling dysfunction in Parkinson's disease
McNaught, K. S. P. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83028-4 · Cited by 1
Self-citation
Parkinson y pesticidas.
Martínez, C. G. (2012) · Repositorio de Patentes de la Universidad de Almería (Universidad de Almería) · Cited by 1
Current Concepts on the Etiology and Pathogenesis of Parkinson Disease
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50008-5 · Cited by 1
Funktionelle Charakterisierung von Mutationen im Synphilin-1- und Parkin-Gen bei der Parkinson-Krankheit : Bedeutung von Proteinaggregation und des Ubiquitin-Proteasomen-Systems für die Pathogenese der Parkinson-Krankheit
Marx, F. P. (2004)
Effetti neuroprotettivi del sulforafane in modelli in vitro di neurodegenerazione
Morroni, F. (2007) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.6092/unibo/amsdottorato/534
Population-based studies on the epidemiology of migraine and Parkinson's disease
Becker, C. (2007) · edoc (University of Basel) · doi:10.5451/unibas-004370546
Parkin and Neurodegeneration
Sriram, S. R., Dawson, V. L., & Dawson, T. M. (2007) · Wiley eBooks · doi:10.1002/9783527619320.ch10c
Molecular Pathology of Dementia
Gouras, G. K. (2005) · KARGER eBooks · doi:10.1159/000084466
Effects of Aggregated Alpha-Synuclein on Cultured Neuronal Cells
Freeman, D. W. (2015) · Loyola eCommons (Loyola University of Chicago)
The Proteasome: Source and a Target of Oxidative Stress?
Halliwell, B. B. (2007) · Springer eBooks · doi:10.1007/0-387-28500-8_6
Pharmacotherapy and Treatment of Parkinson's Disease
Au, W. L., & Calne, D. B. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn062
Muerte celular: blanco terapéutico en neurodegeneración y sepsis
Arboleda, G., & Matheus, L. M. (2005) · Desafíos (Universidad del Rosario)
Los cuerpos de Marinesco. Estudio de 8 casos y revisión de la literatura
Garcia-Miralles, N., Ortega-Medina, L., & Martínez-Martínez, A. (2014) · Revista Española de Patología · doi:10.1016/j.patol.2013.08.003
Systemic Exposure of Environmental Toxins Implies a Pathogenic Model for Parkinson's Disease:
Kamrath, J., Dawson, V. L., Johnson, B. L., & Russell, G. J. (2008)
First in Molecular Medicine Review Series
Kahle, P. J., & Haass, C. (2004)
Ubiquitination by Parkin — Implications in Parkinson’s Disease
Ravichandran, S., Dawson, T. M., & Dawson, V. L. (2006) · Springer eBooks · doi:10.1007/0-387-28500-8_13
Novel mechanisms of quinone toxicity
Xiong, R. (2015) · doi:10.25677/pwc8-7f10
UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL INSTITUTO DE CIÊNCIAS BÁSICAS DA SAÚDE DEPARTAMENTO DE BIOQUÍMICA PROF. TUISKON DICK PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS BIOLÓGICAS: BIOQUÍMICA CARACTERIZAÇÃO DA DIFERENCIAÇÃO NEURONAL INDUZIDA POR ÁCIDO RETINÓICO DA LINHAGEM DE NEUROBLASTOMA HUMANO SH-SY5Y E SEU USO COMO FERRAMENTA PARA PESQUISA EM NEUROCIÊNCIAS
Lopes, F. M. (2012)
[Mechanical ventilation in acute decompensation in chronic obstructive bronchopneumopathy].
Chevrolet, J. C. (1985) · PubMed
EFECTO DE LA ADMINISTRACIÓN CRÓNICA DE LEVODOPA SOBRE LA ACTIVIDAD FUNCIONAL DE LA VÍA NIGROESTRIADA EN MACACOS CON PARKINSONISMO INDUCIDO POR MPTP
Fernández, M. R. (2010)
PAPEL DE LA PROTEÍNA PARKINA EN LA FUNCIÓN CELULAR DE LAS NEURONAS DOPAMINÉRGICAS. SUSCEPTIBILIDAD A LA MUERTE CELULAR
de Bioquímica, D. (2006)
Protein Misfolding, Mitochondrial Disturbances, And Kynurenines In The Pathogenesis Of Neurodegenerative Disorders
Gárdián, G., Sas, K., Toldi, J., & Vécsei, L. (2009) · doi:10.1093/acprof:oso/9780195326697.003.0018
Proteases in Neuropathophysiology
Sarkar, A., Ghosh, S., Dutta, S., & Sil, P. C. (2017) · Springer eBooks · doi:10.1007/978-981-10-3162-5_7
Parkinson Hastalığı ve İlişkili Olduğu Genler
Kurman, Y. (2018) · Düzce Üniversitesi Bilim ve Teknoloji Dergisi · doi:10.29130/dubited.359368
Experimental Models and New, Emerging Therapies for Parkinson Disease
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50012-7
Quinone Reductases
Ross, D., & Siegel, D. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.01967-x
The Ubiquitin–Proteasome System in Parkinson's Disease
McNaught, K. S. P. (2007) · Wiley eBooks · doi:10.1002/9783527619320.ch8c
Self-citation
Parkinson's Disease
(2006) · Wiley eBooks · doi:10.1002/9780470041000.cedt084
Parkin and Neurodegeneration
Sriram, S. R., Dawson, V. L., & Dawson, T. M. (2007) · Wiley eBooks · doi:10.1002/9783527620234.ch10
Quinone Reductases
Ross, D., & Siegel, D. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00019-x
Current Medicinal Plants in the Treatment of Parkinson’s Disease
Dalar, A., & Mükemre, M. (2024) · doi:10.69860/nobel.9786053359241.8
The relationship between herpesviruses and Parkinson’s disease: prevalence, viral load, and clinical implications
Madani, S., Amini, K., Habibi, S. A. H., Shahhosseiny, M. H., & Mohammadian, T. (2026) · Acta Virologica · doi:10.3389/av.2026.14499

Authors: McNaught, K. S. P., & Olanow, C. W.
Affiliations: Icahn School of Medicine at Mount Sinai (US)
Corresponding author: Olanow, C. Warren
ORCID: Olanow, C. Warren
Venue: Annals of Neurology
Publisher: Wiley
Published: 2003
Volume: 53
Issue: S3
Pages: S73-S86
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.10512
OpenAlex: W2135387829
Cited by: 203
References: 96
Citations by year: 2026: 2 · 2025: 1 · 2024: 3 · 2023: 2 · 2021: 2 · 2020: 7 · 2019: 1 · 2018: 5 · 2017: 3 · 2016: 3 · 2015: 5 · 2014: 5 · 2013: 3 · 2012: 6
FWCI: 3.60
Type: journal article
Language: en
Open access: closed
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4626 d)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ns033772-09)
National Institute of Neurological Disorders and Stroke (NS 33772)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords: Parkinson's disease, ubiquitin-proteasome system, alpha-synuclein, Parkin, UCHL1, substantia nigra pars compacta, Lewy bodies, familial Parkinson's disease, sporadic Parkinson's disease, protein aggregation, neuroprotection
MeSH terms: Cysteine Endopeptidases, Humans, Ligases, Multienzyme Complexes, Nerve Degeneration, Nerve Tissue Proteins, Parkinson Disease, Peptide Hydrolases, Substantia Nigra, Thiolester Hydrolases, Lewy Bodies, Point Mutation, Ubiquitin Thiolesterase, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Synucleins, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks